Riskpilot← Back to searchSign inGet full accessZP SPV 1 K/S
K/SActiveCVR 36407727Sydmarken 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 2014— employees
Revenue 2025
DKK 0
EBITDA margin
—
-5% vs 2024
Equity ratio
88.1%
Financial strength
Net profit 2025
DKK -311K
-117% vs 2024
| Revenue | DKK 0 | — |
| EBITDA | DKK -295K | -5% |
| Net profit | DKK -311K | -117% |
| Total assets | DKK 3,8M | -7% |
| Equity | DKK 3,3M | -9% |
| Employees | — | — |
Legal name
ZP SPV 1 K/S
CVR number
36407727
Legal form
Kommanditselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15. oktober 2014
Share capital
—
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Kommanditselskabet tegnes af komplementaren.
Company purpose
Kommanditselskabets formål er at eje (direkte eller indirekte) rettigheder i eller til medicinske produkter, herunder IP rettigheder, eller til royalty betalinger, milestone betalinger og andre betalinger hidrørende fra sådanne produkter. Kommanditselskabets formål er endvidere at indgå kontrakter relateret til sådanne medicinske produkter, IP rettigheder og/eller økonomiske rettigheder.
Address
Sydmarken 11
Email
info@zealandpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4.216 | 0 | 61.228 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 4.169 | -269 | 60.950 | -282 | -295 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 4.169 | -269 | 60.950 | -282 | -295 |
| Net financials | 291 | 2.203 | -3.310 | 2.073 | -16 |
| Profit before tax | 4.460 | 1.934 | 57.640 | 1.791 | -311 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 4.460 | 1.934 | 57.640 | 1.791 | -311 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4.430 | 30.902 | 88.784 | 4.078 | 3.774 |
| Equity | 4.400 | 30.805 | 88.445 | 3.636 | 3.325 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 30 | 97 | 339 | 442 | 449 |
| Total debt | 30 | 97 | 339 | 442 | 449 |
EBITDA margin
-29500000.0%
This company
15.8%
Market median
-186708961% vs market
20212025
Equity ratio
88.1%
This company
38.2%
Market median
+131% vs market
20212025
Return on equity
-9.4%
This company
18.4%
Market median
-151% vs market
20212025
Net profit margin
-31100000.0%
This company
8.1%
Market median
-383950717% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AS Management | Management | 2022 |
HW Management | Management | 2023 |
| Former (5) | ||
MD Management | Management | 2021 – 2022 |
MP Management | Management | 2017 – 2019 |
IM Management | Management | 2019 – 2019 |
ED Management | Management | 2019 – 2022 |
BM Management | Management | 2017 – 2019 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ZEALAND PHARMA A/S
ZP SPV 1 K/S Board members of ZP SPV 1 K/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Matthew Donald Dallas | Management | 0 companies |
| Mats Peter Blom | Management | 0 companies |
| Adam Sinding Steensberg | Management | 0 companies |
| Ivan Mourits Møller | Management | 0 companies |
| Henriette Wennicke | Management | 0 companies |
| Emmanuel Dulac | Management | 0 companies |
| Britt Meelby Jensen | Management | 0 companies |